The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis

OBJECTIVE: Trastuzumab-containing treatment regimens have been shown to improve survival outcomes in HER2-positive breast cancer (BC). It is much easier to infuse a fixed one-vial dose to every patient on a regular schedule in the general clinical setting. The aims of this study were evaluating the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yi-Ying, Huang, Tzu-Chuan, Tsai, Tsung-Neng, Chen, Jia-Hong, Dai, Ming-Shen, Chang, Ping-Ying, Ho, Ching-Liang, Ye, Ren-Hua, Chung, Tsai-Rong, Chen, Yeu-Chin, Chao, Tsu-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783010/
https://www.ncbi.nlm.nih.gov/pubmed/26953588
http://dx.doi.org/10.1371/journal.pone.0151112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783010/
https://www.ncbi.nlm.nih.gov/pubmed/26953588
http://dx.doi.org/10.1371/journal.pone.0151112

Ejemplares similares